Punicalagin treatment improved the liver functions of type-2 diabetic mice (T2DM) and protected high-glucose-treated HepG2 cells through the Akt/FoxO3a signalling pathway [231]. This evidence concerns the gene FOXO3 and type 2 diabetes mellitus.